Anixa Biosciences (ANIX) Change in Account Payables (2017 - 2025)
Anixa Biosciences' (ANIX) quarterly Change in Account Payables came in at -$111000.0 in Q4 2025, down 149.78% YoY from $223000.0 in Q4 2024, and down 1287.5% on a QoQ basis from -$8000.0 in Q3 2025.
Anixa Biosciences (ANIX) Change in Account Payables (2017 - 2025) Analysis & Trends
Anixa Biosciences (ANIX) has 9 years of Change in Account Payables data on file, last reported at -$111000.0 in Q4 2025.
- Quarterly Change in Account Payables fell 149.78% year-over-year to -$111000.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was -$360000.0 (down 212.85% YoY) and the FY2025 annual result came in at -$360000.0, down 212.85% from the prior year.
- Change in Account Payables retreated to -$111000.0 in Q4 2025, from -$8000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $368000.0 in Q1 2022 to a low of -$412000.0 in Q2 2022.
- A 5-year average of -$3350.0 and a median of $15000.0 in 2022 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2021 — Change in Account Payables surged 227.56% — and 2022, when it sank 456.76%.
- Tracing ANIX's Change in Account Payables over 5 years: stood at -$71000.0 in 2021, then soared by 153.52% to $38000.0 in 2022, then jumped by 194.74% to $112000.0 in 2023, then surged by 99.11% to $223000.0 in 2024, then slumped by 149.78% to -$111000.0 in 2025.
- The last three Change in Account Payables figures came in at -$111000.0 (Q4 2025), -$8000.0 (Q3 2025), and -$316000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | -111,000.00 |
| Oct 31, 2025 | -111,000.00 |
| Jul 31, 2025 | -8,000.00 |
| Jul 31, 2025 | -8,000.00 |
| Apr 30, 2025 | -316,000.00 |
| Apr 30, 2025 | -316,000.00 |
| Jan 31, 2025 | 75,000.00 |
| Jan 31, 2025 | 75,000.00 |
| Oct 31, 2024 | 223,000.00 |
| Oct 31, 2024 | 223,000.00 |
| Jul 31, 2024 | 87,000.00 |
| Jul 31, 2024 | 87,000.00 |
| Apr 30, 2024 | -149,000.00 |
| Apr 30, 2024 | -149,000.00 |
| Jan 31, 2024 | 158,000.00 |
| Jan 31, 2024 | 158,000.00 |
| Oct 31, 2023 | 112,000.00 |
| Oct 31, 2023 | 112,000.00 |
| Jul 31, 2023 | -102,000.00 |
| Jul 31, 2023 | -102,000.00 |